U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C18H20N4O2S
Molecular Weight 356.442
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PF-5212377

SMILES

CC1=NC2=C(C=CC=C2N1S(=O)(=O)C3=CC=CC=C3)N4CCNCC4

InChI

InChIKey=MAYQIFVKVAUMPD-UHFFFAOYSA-N
InChI=1S/C18H20N4O2S/c1-14-20-18-16(21-12-10-19-11-13-21)8-5-9-17(18)22(14)25(23,24)15-6-3-2-4-7-15/h2-9,19H,10-13H2,1H3

HIDE SMILES / InChI

Molecular Formula C18H20N4O2S
Molecular Weight 356.442
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Approval Year

Substance Class Chemical
Created
by admin
on Sat Dec 16 12:05:31 GMT 2023
Edited
by admin
on Sat Dec 16 12:05:31 GMT 2023
Record UNII
4JEH3BL51N
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
PF-5212377
Code English
1H-BENZIMIDAZOLE, 2-METHYL-1-(PHENYLSULFONYL)-4-(1-PIPERAZINYL)-
Systematic Name English
PF-05212377
Code English
Code System Code Type Description
CAS
1226793-34-5
Created by admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
PRIMARY
ChEMBL
CHEMBL3545344
Created by admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
PRIMARY
PUBCHEM
46203710
Created by admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
PRIMARY
SMS_ID
300000041347
Created by admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
PRIMARY
FDA UNII
4JEH3BL51N
Created by admin on Sat Dec 16 12:05:32 GMT 2023 , Edited by admin on Sat Dec 16 12:05:32 GMT 2023
PRIMARY
Related Record Type Details
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MINOR
METABOLIC ENZYME -> SUBSTRATE
MAJOR
TARGET -> INHIBITOR
Full antagonist SAM-760 completed phase I trials with no adverse effects at doses of up to 50 mg daily. Pfizer terminated a phase II trial after SAM-760 30 mg/day failed to produce an improvement in cognition in patients already taking a stable dose of donepezil.
Related Record Type Details
ACTIVE MOIETY